LivaNova (LIVN) to Announce Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect LivaNova to announce earnings of $1.08 per share and revenue of $380.5370 million for the quarter. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the firm posted $0.88 EPS. On average, analysts expect LivaNova to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

LivaNova Trading Up 0.2%

LivaNova stock opened at $82.25 on Wednesday. LivaNova has a 52-week low of $41.01 and a 52-week high of $85.27. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $4.52 billion, a price-to-earnings ratio of 41.23 and a beta of 0.86. The firm has a 50-day moving average price of $78.66 and a two-hundred day moving average price of $69.83.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On LivaNova

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after purchasing an additional 544,033 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after purchasing an additional 496,165 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in LivaNova by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company’s stock worth $110,014,000 after purchasing an additional 66,755 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in LivaNova by 4.5% during the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after buying an additional 47,323 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Robert W. Baird decreased their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Finally, Mizuho upped their price objective on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $81.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.